Skip to main content
ArticleOPEN ACCESS

Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

Nature Reviews Clinical Oncology
DOI: 10.1038/NRCLINONC.2017.188
48Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Nature Reviews Clinical Oncology http://dx.doi.org/10.1038/nrclinonc.2017.175 (2017) In the online and PDF versions of this Review, in the ‘Acquired resistance’ subsection, RETI788N was erroneously written as RETI887N, and the ROS1G2032R mutation was written as ROS1D2033N. This information has now been corrected in the online and PDF versions of the Review.

Cite

CITATION STYLE

APA

Drilon, A., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W. (2018, March 1). Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nature Reviews Clinical Oncology. Nature Research. https://doi.org/10.1038/NRCLINONC.2017.188

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free